Archives20242023202220212020201920182017201620152014201320122011 March 10, 2016First European site opened in France and Patient Recruitment Commences in Lupuzor’s™ Pivotal Phase III Study Read More March 01, 2016Confirmation of EIS and VCT Qualifying Status and Issue of Equity. £8.4 million total proceeds raised by ImmuPharma within the recent Placing and Subscription Read More February 23, 2016Result of GM Read More February 15, 2016First US Patients Commence Dosing in Lupuzor’s™ Pivotal Phase III Study Read More February 15, 2016First US Patients Commence Dosing in Lupuzor’s™ Pivotal Phase III Study Read More February 05, 2016Placing and Subscription Raises £8.3 million Read More February 05, 2016Proposed Placing and Subscription and Notice of General Meeting: 22 February 2016 Read More December 15, 2015Over 70 Lupus Specialists Gather in Paris for Lupuzor’s™ Phase III Investigators Meeting Read More December 07, 2015Lupuzor™ Pivotal Phase III Trial Recruiting First US Lupus Patients Read More November 04, 2015Lupuzor™ Phase III Pivotal Trial Update Read More October 23, 2015Board Change Read More September 30, 2015Tim McCarthy Appointed as Non-executive Chairman Read More 1…1617181920…22
March 10, 2016First European site opened in France and Patient Recruitment Commences in Lupuzor’s™ Pivotal Phase III Study Read More
March 01, 2016Confirmation of EIS and VCT Qualifying Status and Issue of Equity. £8.4 million total proceeds raised by ImmuPharma within the recent Placing and Subscription Read More
February 05, 2016Proposed Placing and Subscription and Notice of General Meeting: 22 February 2016 Read More
December 15, 2015Over 70 Lupus Specialists Gather in Paris for Lupuzor’s™ Phase III Investigators Meeting Read More
